1. Home
  2. MESO vs PBI Comparison

MESO vs PBI Comparison

Compare MESO & PBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • PBI
  • Stock Information
  • Founded
  • MESO 2004
  • PBI 1920
  • Country
  • MESO Australia
  • PBI United States
  • Employees
  • MESO N/A
  • PBI N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • PBI Office Equipment/Supplies/Services
  • Sector
  • MESO Health Care
  • PBI Miscellaneous
  • Exchange
  • MESO Nasdaq
  • PBI Nasdaq
  • Market Cap
  • MESO 1.4B
  • PBI 1.5B
  • IPO Year
  • MESO N/A
  • PBI N/A
  • Fundamental
  • Price
  • MESO $10.64
  • PBI $10.30
  • Analyst Decision
  • MESO Buy
  • PBI
  • Analyst Count
  • MESO 4
  • PBI 0
  • Target Price
  • MESO $18.00
  • PBI N/A
  • AVG Volume (30 Days)
  • MESO 226.6K
  • PBI 2.2M
  • Earning Date
  • MESO 02-26-2025
  • PBI 05-07-2025
  • Dividend Yield
  • MESO N/A
  • PBI 2.23%
  • EPS Growth
  • MESO N/A
  • PBI N/A
  • EPS
  • MESO N/A
  • PBI N/A
  • Revenue
  • MESO $5,670,000.00
  • PBI $1,998,749,000.00
  • Revenue This Year
  • MESO $178.09
  • PBI N/A
  • Revenue Next Year
  • MESO $305.06
  • PBI $0.60
  • P/E Ratio
  • MESO N/A
  • PBI $17.81
  • Revenue Growth
  • MESO N/A
  • PBI 13.20
  • 52 Week Low
  • MESO $5.78
  • PBI $4.62
  • 52 Week High
  • MESO $22.00
  • PBI $11.01
  • Technical
  • Relative Strength Index (RSI)
  • MESO 40.85
  • PBI 67.15
  • Support Level
  • MESO $10.60
  • PBI $10.10
  • Resistance Level
  • MESO $11.26
  • PBI $10.55
  • Average True Range (ATR)
  • MESO 0.41
  • PBI 0.29
  • MACD
  • MESO -0.06
  • PBI 0.09
  • Stochastic Oscillator
  • MESO 12.00
  • PBI 83.66

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About PBI Pitney Bowes Inc.

Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.

Share on Social Networks: